Back to News
Market Impact: 0.2
Haemonetics Consensus Price Target Raised 24.88% to $145.63
Source: Nasdaq
Analyst InsightsAnalyst Estimates
Fintel's aggregate one-year analyst price target for Haemonetics was revised up 24.88% to $145.63 per share from $116.62, with the prior estimate dated September 29, 2026. The article provides no share-price reaction or further context.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
HAE0.35
More News
- SpaceX bear flips to big bull because of AI business. Analyst now sees 70% gain
- Williams Trading cuts Deckers Outdoor stock price target on weak DTC trends
- Jefferies raises Zymeworks stock price target on Roche deal
- Truist raises United Rentals stock price target on strong margins
- Century Casinos receives Nasdaq notice for minimum market value deficiency
- GM stock analysis: cheap valuation meets falling estimates after earnings drop